Salvador Borges-Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Salvador Borges-Neto has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Robert Pagnanelli
Duke University Health System
4 shared publications- Jorge Daniel Oldan
Department of Radiology, University of North Carolina, Chapel Hill, NC, 27599, USA
3 shared publications Terence Wong
Department of Medicine, Division of Hematology and Oncology, Duke University Medical Center , Durham, North Carolina
3 shared publicationsAndrea Tisch
2 shared publicationsDonna Hollis
2 shared publicationsLinda K. Shaw
2 shared publications
Latest Publications
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (6) , e012002
Atypical Presentation of an Increasingly Recognized Disease: Transthyretin Amyloidosis Presenting With 18F-Fluorodeoxyglucose Uptake on Cardiac Positron Emission Tomography and Focal Late Gadolinium Enhancement on Cardiac Magnetic Resonance
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (6) , e012002
Atypical Presentation of an Increasingly Recognized Disease: Transthyretin Amyloidosis Presenting With 18F-Fluorodeoxyglucose Uptake on Cardiac Positron Emission Tomography and Focal Late Gadolinium Enhancement on Cardiac Magnetic Resonance
- Open Access
- 22 July 2022
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 30 (1) , 368-370
Bone scintigraphy imaging and transthyretin-related (ATTR) cardiac amyloidosis: New tricks from an old tool?
- 22 July 2022
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 30 (1) , 368-370
Open AccessBone scintigraphy imaging and transthyretin-related (ATTR) cardiac amyloidosis: New tricks from an old tool?
- 11 October 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (3) , e494-e501
Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG
Context Prognosis of metastatic pheochromocytoma/paraganglioma following 131-Iodine metaiodobenzylguanidine (MIBG) is incompletely characterized due to small samples and shorter follow-up in these rare, often indolent tumors. Objective To describe long-term survival, frequency, and prognostic impact of imaging, biochemical, and symptomatic response to 131-I MIBG. Design Retrospective chart and imaging review at a tertiary referral center. Patients Six hundred sixty-eight person-years of follow-up in 125 patients with metastatic pheochromocytoma/paraganglioma with progression through prior multimodal treatment. Intervention Median 18 800 MBq 131-I MIBG. Main Outcome Measures Overall survival, Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST) imaging response, symptomatic response per chart review, and biochemical response (20% change over 2 consecutive assays of catecholamines, vanillylmandelic acid, metanephrines, or chromogranin A). Results Median survival standard deviation [SD] from diagnosis was 11.5 years [2.4]; following metastasis, 6.5 years [0.8]; post treatment, 4.3 years [0.7]. Among 88 participants with follow-up imaging, 1% experienced complete response, 33% partial response, 53% stability, and 13% progression. Fifty-one percent showed subsequent progression, median progression-free survival [SD] of 2.0 years [0.6]. Stability/response vs progression at first imaging follow-up (3–6 months) predicted improved survival, 6.3 vs 2.4 years (P = 0.021). Fifty-nine percent of 54 patients demonstrated biochemical response. Fifty percent of these relapsed, with median time to laboratory progression [SD] of 2.8 years [0.7]. Biochemical response did not predict extended survival. Seventy-five percent of 83 patients reported improvement in pretreatment symptoms, consisting primarily of pain (42%), fatigue (27%), and hypertension (14%). Sixty-one percent of these patients experienced subsequent symptomatic progression at median [SD] 1.8 years [0.4]. Symptomatic response did not predict extended survival. Conclusions Imaging, symptomatic, and laboratory response to multimodal treatment including high-dose 131-I MIBG were achieved on long-term follow-up in metastatic pheochromocytoma or paraganglioma. Imaging response at 3 to 6 months was prognostic.
- 11 October 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (3) , e494-e501
Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG
Context Prognosis of metastatic pheochromocytoma/paraganglioma following 131-Iodine metaiodobenzylguanidine (MIBG) is incompletely characterized due to small samples and shorter follow-up in these rare, often indolent tumors. Objective To describe long-term survival, frequency, and prognostic impact of imaging, biochemical, and symptomatic response to 131-I MIBG. Design Retrospective chart and imaging review at a tertiary referral center. Patients Six hundred sixty-eight person-years of follow-up in 125 patients with metastatic pheochromocytoma/paraganglioma with progression through prior multimodal treatment. Intervention Median 18 800 MBq 131-I MIBG. Main Outcome Measures Overall survival, Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST) imaging response, symptomatic response per chart review, and biochemical response (20% change over 2 consecutive assays of catecholamines, vanillylmandelic acid, metanephrines, or chromogranin A). Results Median survival standard deviation [SD] from diagnosis was 11.5 years [2.4]; following metastasis, 6.5 years [0.8]; post treatment, 4.3 years [0.7]. Among 88 participants with follow-up imaging, 1% experienced complete response, 33% partial response, 53% stability, and 13% progression. Fifty-one percent showed subsequent progression, median progression-free survival [SD] of 2.0 years [0.6]. Stability/response vs progression at first imaging follow-up (3–6 months) predicted improved survival, 6.3 vs 2.4 years (P = 0.021). Fifty-nine percent of 54 patients demonstrated biochemical response. Fifty percent of these relapsed, with median time to laboratory progression [SD] of 2.8 years [0.7]. Biochemical response did not predict extended survival. Seventy-five percent of 83 patients reported improvement in pretreatment symptoms, consisting primarily of pain (42%), fatigue (27%), and hypertension (14%). Sixty-one percent of these patients experienced subsequent symptomatic progression at median [SD] 1.8 years [0.4]. Symptomatic response did not predict extended survival. Conclusions Imaging, symptomatic, and laboratory response to multimodal treatment including high-dose 131-I MIBG were achieved on long-term follow-up in metastatic pheochromocytoma or paraganglioma. Imaging response at 3 to 6 months was prognostic.
- Open Access
- 19 December 2018
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 27 (2) , 573-574
How low can we go?
- 19 December 2018
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 27 (2) , 573-574
Open AccessHow low can we go?
- Open Access
- 18 May 2018
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 59 (11) , 1708-1713
Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
Purpose: This retrospective analysis identifies predictors of survival in a cohort of patients with mIBG positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with I-131 mIBG therapy, in order to inform treatment selection and post-treatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from n = 211 P/GEP-NET patients treated with mIBG between 1991-2014. For patients with computed tomography (CT) follow up (n = 125), imaging response was assessed by Response Evaluation Criteria on Solid Tumors (RECIST) 1.1 where images were available (n = 76) or by chart review of the radiology report where images could not be reviewed (n = 49). Kaplan Meier analysis and Cox multivariate regression estimated survival and progression free survival benefits predicted by initial imaging, biochemical and symptomatic response. Results: All patients had stage IV disease at time of treatment. Median survival was 29 months from time of treatment. 71% of patients demonstrated symptomatic response with median duration of symptomatic relief of 12 months. Symptomatic response at first follow-up predicted a survival benefit of 30 months (pConclusion: Therapeutic I-131-mIBG for metastatic pulmonary or gastroenteropancreatic neuroendocrine tumors appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up each help prognosticate expected survival following mIBG therapy. Multiple rounds of mIBG are associated with prolonged survival; it is unclear whether this represents cause or effect.
- 18 May 2018
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 59 (11) , 1708-1713
Open AccessPredictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
Purpose: This retrospective analysis identifies predictors of survival in a cohort of patients with mIBG positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with I-131 mIBG therapy, in order to inform treatment selection and post-treatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from n = 211 P/GEP-NET patients treated with mIBG between 1991-2014. For patients with computed tomography (CT) follow up (n = 125), imaging response was assessed by Response Evaluation Criteria on Solid Tumors (RECIST) 1.1 where images were available (n = 76) or by chart review of the radiology report where images could not be reviewed (n = 49). Kaplan Meier analysis and Cox multivariate regression estimated survival and progression free survival benefits predicted by initial imaging, biochemical and symptomatic response. Results: All patients had stage IV disease at time of treatment. Median survival was 29 months from time of treatment. 71% of patients demonstrated symptomatic response with median duration of symptomatic relief of 12 months. Symptomatic response at first follow-up predicted a survival benefit of 30 months (pConclusion: Therapeutic I-131-mIBG for metastatic pulmonary or gastroenteropancreatic neuroendocrine tumors appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up each help prognosticate expected survival following mIBG therapy. Multiple rounds of mIBG are associated with prolonged survival; it is unclear whether this represents cause or effect.
- 14 February 2018
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 26 (4) , 1240-1242
A troubled marriage: When electrical and mechanical dyssynchrony don’t go along
- 14 February 2018
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 26 (4) , 1240-1242
A troubled marriage: When electrical and mechanical dyssynchrony don’t go along
- Open Access
- 30 January 2017
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 25 (3) , 1038-1
Mechanical dyssynchrony according to validated cut-off values using gated SPECT myocardial perfusion imaging
- 30 January 2017
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 25 (3) , 1038-1
Open AccessMechanical dyssynchrony according to validated cut-off values using gated SPECT myocardial perfusion imaging
- 27 June 2015
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 23 (6) , 1280-1287
Prognostic value of the cadmium-zinc-telluride camera: A comparison with a conventional (Anger) camera
- 27 June 2015
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 23 (6) , 1280-1287
Prognostic value of the cadmium-zinc-telluride camera: A comparison with a conventional (Anger) camera
- Open Access
- 12 June 2015
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 22 (6) , 1259-1261
In search of the perfect indicators of left ventricular mechanical dyssynchrony
- 12 June 2015
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 22 (6) , 1259-1261
Open AccessIn search of the perfect indicators of left ventricular mechanical dyssynchrony
- 1 March 2015
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (3) , 220-223
Definitive Diagnosis of Cerebrospinal Fluid Leak Into the Pleural Space Using 111In-DTPA Cisternography
A 58-year-old woman with a calcified disk extrusion causing severe spinal stenosis underwent T8 to T9 diskectomy and spinal fusion. A postoperative pseudomeningocele was treated with lumbar drain and fibrin glue. Performed for persistent right pleural effusion, CT myelogram failed to show communication between the cerebrospinal fluid (CSF) and pleural space--even on 2-hour delayed images. Subsequent 111In-DTPA cisternogram clearly demonstrated CSF leakage into the right pleural space at 2 hours, and surgical repair yielded good results. Radionuclide cisternography is a highly useful method to detect CSF leak, especially when it is occult on CT yet suspected clinically.
- 1 March 2015
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (3) , 220-223
Definitive Diagnosis of Cerebrospinal Fluid Leak Into the Pleural Space Using 111In-DTPA Cisternography
A 58-year-old woman with a calcified disk extrusion causing severe spinal stenosis underwent T8 to T9 diskectomy and spinal fusion. A postoperative pseudomeningocele was treated with lumbar drain and fibrin glue. Performed for persistent right pleural effusion, CT myelogram failed to show communication between the cerebrospinal fluid (CSF) and pleural space--even on 2-hour delayed images. Subsequent 111In-DTPA cisternogram clearly demonstrated CSF leakage into the right pleural space at 2 hours, and surgical repair yielded good results. Radionuclide cisternography is a highly useful method to detect CSF leak, especially when it is occult on CT yet suspected clinically.